References
- Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 2006; 23(2): 70-83.
- DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan MF. Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival. Ann Surg. 2000; 231(1): 51-58.
- Lv M, Wu C, Zheng Y, Zhao N. Incidence and survival analysis of gastrointestinal stromal tumors in Shanghai: A population-based study from 2001 to 2010. Gastroenterol Res Pract. 2014; 2014: 83416
- Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer. 1999; 83(1): 18-29.
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359-E386.
- Zhao X, Yue C. Gastrointestinal stromal tumor. J Gastrointest Oncol. 2012; 3(3): 189-208.
- ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23(Suppl 7): vii49-vii55.
- Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demerti G, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000; 156(3): 791-795.
- Heinrich MC, Corless CL, Demetri GD, Blanke CD, von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21(23): 4342-4349.
- Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousová M, Holubec L, et al. Tumor markers in colorectal cancer, gastric cancer and gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer. 2014; 134(11): 2513-2522.
- Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen C-J, Joseph N, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003; 299(5607): 708-710.
- Moutinho C, Mateus AR, Milanezi F, Carneiro F, Seruca R, Suriano G. Epidermal growth factor receptor structural alterations in gastric cancer. BMC Cancer. 2008; 8(10): 10.
- Cohen RB. Epidermal growth factor receptor as a therapeutic target in colorectal cancer. Clin Colorectal Cancer. 2003; 2(4): 246-251.
- Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer. 2001; 37(Suppl 4): S3-S8.
- Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol. 1997; 8(12): 1197-1206.
- Yamaoka T, Ohba M, Ohmori T. Molecular-targeted therapies for epidermal growth factor receptor and its resistance mechanisms. Int J Mol Sci. 2017; 18(11): 2420.
- Edris B, Espinosa I, Mühlenberg T, Mikels A, Lee CH, Steigen SE, et al. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. 2012; 227(2): 223-233.
- Rubin BP, Heinrich MC, Corless CL. Gastrointestinal stromal tumour. Lancet. 2007; 369(9574): 1731-1741.
- Hynes NE, Lane HA. ERBB receptors and cancer: The complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5): 341-354.
- Jiang Z, Li C, Li F, Wang X. EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: A systematic review and meta analysis. PLoS One. 2013; 8(2): e56205.
- Temel S, Uren D, Yakicier MC. Genetics and molecular basis of gastric cancer. In: Canbay E, Zilberstein B, Sossai P, Jinjuvadia K, Catterjee I, Editors. Overview on Gastric Cancer, 3rd ed. Las Vegas, NV, USA: Open Access eBooks. 2018: 1-13.
- Metro G. EGFR targeted therapy for lung cancer: are we almost there? Transl Lung Cancer Res. 2018; 7(Suppl 2): S142-S145.
- Ergin K, Gürsoy E, Başimoǧlu Koca Y, Başaloǧlu H, Seyrek K. Immunohistochemical detection of insulin-like growth factor-I, transforming growth factor-beta2, basic fibroblast growth factor and epidermal growth factor-receptor expression in developing rat ovary. Cytokine. 2008; 43(2): 209-214.
- Shi S-S, Wu N, He Y, Wei X, Xia Q-Y, Wang X, et al. EFGR gene mutation in gastrointestinal stromal tumors. Histopathology. 2017; 71(4): 553-561.
- Apicella M, Corso S, Giordano S. Targeted therapies for gastric cancer: Failures and hopes from clinical trials. Oncotarget. 2017; 8(34): 57654-57669.
- Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014; 513(7517): 202-209.
- Huss S, Künstlinger H, Warderlmann E, Kleine MA, Binot E, Merkelbach-Bruse S, et al. A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (pD419del). Mod Pathol. 2013; 26(7): 1004-1012.